Prime Medicine Stock Price, News & Analysis

Prime Medicine (Nasdaq: PRME) announced that Allan Reine, M.D., Chief Executive Officer, will speak in a fireside chat at the Jefferies Global Healthcare Conference on Tuesday, November 18, 2025 at 12:00 noon GMT (7:00 a.m. ET) in London.

A live audio webcast will be available under “Events & Presentations” in the News & Events section of the company website at www.primemedicine.com, and a replay will be accessible on the website for 90 days after the event.

Prime Medicine (NASDAQ: PRME) reported Q3 2025 results and provided program updates on Nov 7, 2025. Key items: WD IND/CTA expected in H1 2026 (corrected timeline) with initial clinical data expected in 2027; PM647 nominated for AATD with IND/CTA planned mid-2026 and first clinical readouts in 2027; new preclinical PM577 data to be presented at AASLD (Nov 9, 2025).

Financials: R&D $44.0M, G&A $11.2M, net loss $50.6M for Q3; cash, cash equivalents and investments totaled $227.0M as of Sep 30, 2025, and management expects cash into 2027 based on current plans. Leadership: appointed Matthew Hawryluk as Chief Business Officer. Virtual KOL event on Nov 12, 2025 at 8:00am ET to discuss WD strategy.

Prime Medicine (Nasdaq: PRME) reported Q3 2025 results and business updates on Nov 7, 2025. Key program milestones include nomination of PM647 for AATD with preclinical restoration of M-AAT into the healthy human range in humanized mice, and new preclinical PM577 data for Wilson’s Disease to be presented at AASLD on Nov 9, 2025.

The company expects to file an IND/CTA for AATD in mid-2026 and for Wilson’s Disease in the first half of 2027, with initial clinical data for both programs expected in 2027. Q3 cash and equivalents were $227.0M, and management says cash of $213.3M as of Sept 30, 2025 is sufficient to fund operations into 2027.

Prime Medicine (Nasdaq: PRME) appointed Matthew Hawryluk, Ph.D., M.B.A. as Chief Business Officer effective Nov 3, 2025. Dr. Hawryluk will lead corporate and business development, corporate strategy, and alliance management to expand Prime Editing through strategic partnerships.

He brings nearly two decades of BD and corporate leadership, including a prior role as CBO at AIRNA where he helped secure an oversubscribed $155 million Series B, and earlier transactions totaling $2.5 billion in potential value at Gritstone bio. The release also notes Prime’s earlier 2025 clinical data showing initial human safety and efficacy for Prime Editing.

Prime Medicine (Nasdaq: PRME) will host a virtual KOL event on Nov 12, 2025 at 8:00am ET to present its liver disease franchise and Wilson’s Disease strategy. The company said it remains on track to file an IND/CTA for PM577 in the first half of 2026, with initial clinical data expected in 2027. Presenters include company management and Dr. Michael Schilsky, covering Prime Editing platform modularity, the unmet need in Wilson’s Disease, and development plans. The live webcast and presentation materials will be available on Prime Medicine’s investor relations site, with an archived replay after the event.

Prime Medicine (Nasdaq: PRME) announced management will participate in two investor conferences in October 2025. A fireside chat at the H.C. Wainwright Genetic Medicines Virtual Conference will be available on demand beginning October 14, 2025, with virtual 1x1 meetings on October 15, 2025. Allan Reine, M.D., will join a panel, “Genome Editing: Next Wave Technologies,” and host 1x1 meetings at Chardan’s 9th Annual Genetic Medicines Conference on October 21, 2025 at 8:45 a.m. ET in New York.

Live audio webcasts and replays will be available under Events & Presentations on the company website, with replays accessible for 90 days after each event.

Prime Medicine (Nasdaq: PRME), a biotechnology company focused on curative genetic therapies, has announced its participation in two upcoming investor conferences in September 2025:

The company will present at Citi's 2025 Biopharma Back to School Conference on September 2 at 4:45 p.m. ET in Boston, and at the Morgan Stanley 23rd Annual Global Healthcare Conference on September 8 at 1:05 p.m. ET in New York. Live webcasts will be available on Prime Medicine's website, with replays accessible for 90 days after each event.

Prime Medicine (NASDAQ: PRME) reported Q2 2025 financial results and significant business updates. The company announced positive clinical data from two patients in their Phase 1/2 CGD trial, demonstrating the first clinical proof-of-concept for Prime Editing technology. Prime Medicine completed a follow-on offering raising $144.2 million and secured up to $24 million in additional funding from the Cystic Fibrosis Foundation.

The company reported a Q2 2025 net loss of $52.6 million, with R&D expenses of $41.4 million and G&A expenses of $13.1 million. Under new CEO Allan Reine's leadership, Prime Medicine is focusing on advancing its liver franchise programs (Wilson's Disease and Alpha-1 Antitrypsin Deficiency) and partnership-funded initiatives. The company's pro-forma cash position of $259.6 million is expected to fund operations into 2027.

Prime Medicine (Nasdaq: PRME) has successfully completed its public offering of 43.7 million shares of common stock at $3.30 per share, including the full exercise of the underwriters' option for 5.7 million additional shares. The biotechnology company, focused on developing curative genetic therapies, raised approximately $144.2 million in gross proceeds before deducting expenses.

The offering included a notable sale of 1,818,181 shares to the Cystic Fibrosis Foundation, for which underwriters received no commissions. TD Cowen and BMO Capital Markets served as joint book-running managers for the offering, which was conducted under Prime Medicine's previously filed shelf registration statement.